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The present study is focused on the characterization of solubilization of poorly soluble drugs, that is, sulfamethoxazole (SMX)
and trimethoprim (TMP) by cyclodextrins (α-, β-, and γ-CDs) and anionic surfactant sodium dodecyl sulfate (SDS). The phase
solubility diagrams drawn from UV spectral measurements are of the AL type and indicate an enhancement of SMX and TMP
solubility in the presence of CDs. Complex formation tendency of TMP with CDs followed the order: γ-CD >β -CD >α -C.
However, the complex formation constant values, for SMX-CD system yielded the diﬀerent aﬃnity and follow the order: β-CD >
γ-CD >α -CD. With taking into consideration of solubilization capacity of SDS micelles, it has been found that the solubility
enhancement of TMP is much higher than that of SMX in the presence of SDS micelles. The binding constants of SMX and TMP
obtained from the Benesi-Hildebrand equation are also conﬁrmed by the estimated surface properties of SDS, employing the
surface tension measurements. In order to elucidate the solubilization characteristics the surface tension measurements were also
performed for nonionic surfactant Triton X-100. Polarity of the microenvironment and probable location of SMX and TMP were
also discussed in the presence of various organic solvents.
1.Introduction
Solubilization of poorly soluble drugs is one of the most
important physicochemical properties for drug development
since more than one-third of drugs are poorly water soluble
or water insoluble. In order to prepare a liquid dosage for-
mulation of these drugs, a solubilization technique is usually
applied. ThemostcommonlyusedtechniquesarepHadjust-
ment, cosolvency, micellization, and complexation [1–4].
Cyclodextrins (CDs) are widely used as complexing agents
for lipophilic and amphiphilic substances and functional
excipients that have gained widespread use and attention
because of their ability to solubilize, and in some instances
stabilize,poorly water-solubledrug candidates enabling both
oral and parenteral formulation [5–9]. CD molecules are
peculiar cyclic oligomers of α-D-glucose; their shapes resem-
ble truncated cones with primary and secondary hydroxyl
groups located around their narrower and wider rim. The
mostlyusednativecyclodextrinsconsistof6,7,and8glucose
units, and, according to the number of monomers in the
macrocycle, they are named as α, β,a n dγ-cyclodextrin,
respectively. These molecules have a hydrophobic inner
cavity, while the large number of hydroxyl groups on the
outer surface makes them water soluble. Due to this special
molecular structure, cyclodextrins are capable of forming
inclusion complexes with many drugs and other compounds
by taking up a lipophilic guest molecule (or its hydrophobic
part) of the appropriate size into the cavity [10–12]. The
chemical structures of CDs are shown in Figure 1.T h e
ability of the CDs to form inclusion complexes with a
variety of organic compounds is based on their ability to
provide a hydrophobic cavity in aqueous solution for a hy-
drophobic guest molecule or hydrophobic moieties in the
guest molecule. Moreover CDs have been used as a model2 The Scientiﬁc World Journal
for proteins and enzymes. The pharmaceutical interest in
CDs extends to enhance the solubility, chemical stability,
and bioavailability of poorly soluble drugs to reduce the
toxicity and control the rate of release of some drugs [13].
Complexation of water-insoluble or poorly soluble drugs
with native or modiﬁed cyclodextrins has been studied by a
large number of workers [14–17], and some of the reports
generated on this topic have been reviewed [18–21].
Micellar solubilization is also a powerful alternative for
dissolving hydrophobic drugs in aqueous environments.
Because of its amphiphilic nature, micelles are known to play
a vital role in many processes of interest in both fundamental
and applied sciences. Micellar system can solubilize poorly
soluble drugs increasing their bioavailability, and they can
be used as a model system for biomembrane, as well as
drug carriers in numerous drug delivery and drug targeting
systems. Micelles are known to have an anisotropic water
distribution within their structure. In other words, the water
concentration decreases from the surface towards the core of
the micelle, with a completely hydrophobic (water-excluded)
core. Consequently, the spatial position of a solubilized drug
in a micelle will depend on its polarity: nonpolar molecules
will be solubilized in the micellar core, and substances with
intermediate polarity will be distributed along the surfactant
molecules in certain intermediate positions. Surfactantssuch
as sodium dodecyl sulfate (SDS) are used as excipients and
usuallyaddedtotheformulationtofacilitatethepreparation,
patient acceptability, and functioning of the dosage form
[4, 22]. The SDS molecule contains a 12-carbon-saturated
alkyl chain bound to a negatively charged sulfonate head
(OSO3
−), and therefore, it is structurally comparable to
many biosurfactants for which it is also used as a model.
In aqueous medium, SDS (Figure 1) forms micelles which
mimic biological membrane system as a model of globular
protein and capable of solubilizing hydrophobic molecules
resulting in a high local concentration. From this point of
view, the interactions of drug with surfactants provide an
insight into more complex biological processes such as the
passage of drugs through cell membranes. The fundamental
event in the interaction of drugs with biological tissues
at the molecular level is their binding to membranes. A
number of studies have been dedicated to drug/surfactant
interactions [23–27]. This is an important issue because
it relates to the mechanism of drug action. Therefore, the
study of surfactant micelles and their role in pharmacy is of
paramount importance, especially with respect to their abil-
ity of solubilizing hydrophobic drugs [15, 28–32]. Despite
the large number of articles devoted to the interaction
of drugs by surfactants or cyclodextrins, the studies that
combine spectroscopy with surface tension measurements
under identical experimental conditions are still missing.
The aim of this work is to improve the eﬀects of diﬀerent
types of excipients such as surfactant and cyclodextrins used
in pharmaceutical applications on the solubilization and
interactions of poorly soluble drugs in aqueous media. To
more precisely analyze and evaluate interactions of drugs in
diﬀerent media, surface tension data are compared for the
SDS and CDs in the presence of SMX and TMP in aqueous
media.ThedependenceofSMXandTMPabsorptionspectra
on the SDS and CDs concentration leads to interesting
correlations with the surface tension measurements in terms
of type of solubilization. For example, the solubilization of
drug may not only involve incorporation into the micellar
interior or cyclodextrins cavity but may also be substantially
due to adsorption at the micelle-water interface or outer
surface of cyclodextrins. Therefore, in this work, poorly
soluble drugs sulfamethoxazole (SMX) and trimethoprim
(TMP) were chosen as model to study their solubilization
characteristics in the presence of SDS micelles and CDs (α,
β,a n dγ-CD) in aqueous media at 298K. The chemical
structures of SMX and TMP are shown in Figure 1.S M X
and TMP possess poor solubility in water; that is, SSMX=
600mg L−1(≈ 2.368 × 10
−3 M) and STMP = 400mg L−1
(≈ 1.377 × 10
−3 M). The combination antibacterial product
containing SMX and TMP in a ﬁxed 5:1 ratio is well known
asCo-trimoxazole.Keepinginmindthescopeofthestudyon
solubilization of poorly soluble drugs SMX and TMP by SDS
micelles and α-, β-, and γ-CDs, the present study is divided
into four sections. In the ﬁrst section, the interaction of ﬁxed
concentration of SMX and TMP (4.0 × 10
−5 M) with SDS
and CDs is discussed using the Benesi-Hildebrand equation
to determine the binding constants of SMX and TMP in
diﬀerent environments. The concentration of 4.0 × 10
−5M
was chosen as a common concentration to study interaction
of two drugs with SDS and CDs to compare their binding
tendency. At this concentration both SMX and TMP are
freely soluble in water. The changes in surface tension of SDS
and CDs in the presence of SMX and TMP are addressed
in the second section to determine the surface excess of
SDS by using the Gibbs adsorption equation. In the third
section, the performance and eﬀect of SDS micelles and
CDs on the solubilization of SMX and TMP at their water
insoluble concentrations range are compared and discussed
using phase solubility diagrams. Finally, in order to gain
further insight about the probable localization of poorly
soluble drugs into the SDS and CDs, it has been monitored
the variation of SMX and TMP absorption spectra in the
presence of various organic solvents. Eﬀect of medium
polarity on the solubilization mechanism is also discussed in
the present study.
2.MaterialandMethods
2.1. Materials. All the experiments were performed with
analytical-grade chemicals and solvents. Trimethoprim [2,
4-diamino-5-(3’, 4’, 5’-trimethoxybenzyl pyrimidine)]
(C14H18N4O3) and sulfomethoxazole [4-amino-N-(5-meth-
ylisoxazol-3-yl)-benzenesulfonamide] (C10H11N3O3S) were
purchased from Sigma (Germany), respectively. α-, β-, and
γ-cyclodextrins were obtained from Sigma-Aldrich. Sodium
dodecyl sulfate and Triton X-100 were Sigma (Germany)
products. Doubly distilled conductivity water was used for
solution preparation.
2.2. Instruments. The spectroscopic measurements were per-
formed on a double-beam UV-Vis spectrophotometer (Shi-
madzu UV-2100 S) equipped with a matched pair of cuvettesThe Scientiﬁc World Journal 3
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Figure 1: Chemical structures of α-CD, β-CD, γ- CD, SDS, TMP, and SMX.
of 10.0mm path length in a water-jacketed thermostatic cell
holder. The reproducibility for λmax of spectra was ±0.1nm.
Allmeasurementsweredoneatleastintriplicate.Thesurface
tension measurements were performed with KSV Instru-
ments computer-controlled tensiometer, model Sigma 701
(Helsinki, Finland) employing the Wilhelmy plate method.
The plate was cleaned by washing with doubly distilled water
followed by heating in an alcohol ﬂame. All surface tension
values reported here are mean quantities of at least three
measurements performed at 298K. The standard deviation
of the mean never deviated ±1.2% of the mean. The
precision of the surface tension apparatus was 0.1mN/m.
2.3. Methods. The interactions of SMX and TMP with SDS
and CDs as well as solubilization experiments have been per-
formed by a combination of surface tension measurements
and UV-absorption spectrophotometry.
2.3.1. Spectrophotometric Measurements. Changes in absorb-
ance of SMX at 265nm and TMP at 274nm were observed
and determined linear between the concentrations of 1.0 ×
10
−5–1.0 × 10
−4 M( R2 = 0.9989). Absorption spectra of
SMX and TMP in aqueous solution with a varying wide
concentration range of SDS, α-, β-, and γ-CDs have been
recorded at 298K (±0.1), keeping the concentration of drugs
(4.0 × 10
−5 M) ﬁxed in each one. Binding constants were
determined from the absorbances of a series of solutions
containing a ﬁxed concentration of drugs and increasing
concentration of SDS, α-, β-, and γ-CDs.
2.3.2. Surface Tension Measurements. Surface tension of
aqueous solutions of CDs and surfactant in the absence
a n dp r e s e n c eo fﬁ x e dc o n c e n t r a t i o n so fS M Xa n dT M P
were measured at 298K by computer-controlled Wilhelmy
plate method in order to determine maximum surface excess
concentration of surfactants and CDs in the presence of each
drug.
2.3.3. Solubility Measurements. Phase-solubility studies of
SMX and TMP in aqueous solutions of CDs and SDS were
carried out according to the Higuchi-Connors procedure
[33]. Various amounts of SDS and CDs were generally
dissolved in distilled water, and excess amounts of SMX and
TMP were loaded in glass vials. The vials were shaken in a
temperature-controlled room at 298K for 24h to achieve the
equilibrium. Appropriate aliquots were then withdrawn and
ﬁltered appropriately diluted with distilled water, and the
total concentration of the drugs in the ﬁltrate was analyzed
by UV absorbance spectrum. The absorbances at 274nm
for TMP and 265nm for SMX were measured, in order to
determine the concentration of the dissolved drugs.4 The Scientiﬁc World Journal
2.4. Theoretical Background
2.4.1. Determination of Binding Constants of Drugs with CDs
and SDS Micelles. The binding constants of drugs to micelle
and/or cyclodextrins can be quantitatively determined using
the Benesi-Hildebrand equation [34] in the following modi-
ﬁed form [25, 35, 36]:
[D]l
A −A0
=
1
Δε
+
1
Kb[C](Δε)
,( 1 )
where [D] and [C] represent the concentrations of drug and
CD or SDS micelles, respectively. In the case of SDS micelles,
C is micellized surfactant concentration; that is, [C] = (total
surfactant concentration-CMC). l is the optical path length
of the solution. A and A0 are the absorbances of drug in
the absence and presence of SDS or CDs, respectively. Δε
is the diﬀerence in molar absorption coeﬃcients between
complexed/bound and free drug. The plot of [D] l/(ΔA)
against 1/[C] was found to be linear in all cases.
2.4.2. Determination of Surface Excess Amount and Minimum
Area per Molecule. On the basis of a plot of the surface
tension, γ, as a function of the equilibrium concentrations
of SDS and CDs in the presence of ﬁxed concentrations
of SMX and TMP, the changes of surface properties,
namely, maximum surface excess concentration (Γmax)a n d
minimum area per molecule (Amin), can be determined by
application of the Gibbs adsorption isotherm [4]:
Γmax =−
1
RT

dγ
d lnC

,( 2 )
where R is the gas constant, T is the temperature in Kelvin,
and C is the concentration of SDS or CD. Changes in min-
imum surface area per molecule can be obtained from the
maximum surface excess concentration at the air-solution
interface, A (˚ A2 molecule−1), and were evaluated from
A =
1
NAΓmax
,( 3 )
where NA is the Avogadro constant.
2.4.3. Drug Solubilization Using Cyclodextrins. Phase solu-
bility diagrams were analyzed to obtain estimates of the
complex formation constants of soluble complexes described
earlier [33, 37]. The linear part of the experimental solubility
isothermssuggeststhatintheseequilibriaCDs-SMXorCDs-
TMP associates of 1:1 molar ratio are dominantly formed.
The K1:1 stability constants for associates of 1:1 molar ratio
have been calculated using the approach oﬀered by Iga et al.
[38]:
K1:1 =
slope

S0

1 −slope
,( 4 )
where S0 is the solubility of the drugs at 298K in the absence
of cyclodextrins and slope means the corresponding slope of
phase-solubilitydiagrams,thatis,theslopeofthedrugmolar
concentration versus CDs molar concentration graph.
2.4.4. Drug Solubilization Using Surfactant. The solubility of
a drug in the presence of a surfactant alone can be expressed
by considering the two-phase model wherein it is assumed
that the micellization is seen only above the critical micellar
concentration (CMC) and that the monomer concentration
is constant irrespective of the total surfactant concentration
above the CMC. For such a system, the total solubility of the
drug in the presence of the surfactant (CS) is given by the
following equation [31, 39]:
ST = KM(CS −CCMC)+S0. (5)
Here, KM,C S,a n dC CMC are the solubilizing capacity of
micelles, surfactant concentration, and critical micelle con-
centration, respectively. Solubilizing capacity of micelles
(KM) determined from the slope of the solubilization curve
will be expressed by M−1 in this paper.
3. Results and Discussion
3.1. Interactions of SMX and TMP with SDS, α-, β-, and
γ-CDs. SMX is an acidic compound, and the spectrum
undergoes a hypsochromic shift with increasing pH, corre-
sponding to the loss of a proton from the –SO2–NH– group,
implyingtheexistenceofelectron-withdrawinggroupsinthe
SMX anion [40, 41]. At pH values above 5.6, SMX exists
predominantly as anionic species; at pH values between 1.7
and 5.6, SMX is uncharged, while at, pH values below 1.7, it
is positively charged [42]. In our experimental conditions,
the medium pH is above 5.7 where more stable SMX
anions exist. TMP is a basic compound, and a proton is
associated with the NH2 substituents in acidic solutions, but
thespectrumshowsabathochromicshiftasthepHincreased
[40]. The basic drug TMP and acidic drug SMX having
the structures shown in Figure 1 exhibit the maximum
absorption bands at 274 and 265nm, respectively. The molar
extinction coeﬃcients (ε0) of TMP at 274nm and SMX at
265nm were calculated as 6.21 × 103 and 15.17 × 103 mol−1
dm3cm−1 in the concentration range of 1.0 × 10
−5–1.0 ×
10
−4 mol dm−3 of the drugs at 298K, respectively. The linear
relation between absorbance and drug concentration (R2 :
0.9998) indicates the validity of Beer’s Law. The eﬀect of
anionic surfactant SDS, at the concentrations varied from
1.0 × 10
−5 to 4.0 × 10
−2 M (from premicellar to micellar
region), on the absorption spectrum of SMX and TMP at
ﬁxed concentration of 4.0 ×10
−5 M was studied. The change
of absorption spectrum of TMP in the presence of various
concentration of SDS was shown in Figure 2(a). TMP exists
in cationic form in aqueous solution. As seen in Figure 2(a)
the absorbance decreased with a small blue shift with the
increase in SDS concentration up to 4mM. It was observed
that the increase in absorbance with the increase in SDS
concentrations above the CMC, λmax of TMP at 274nm
shifted to 270nm. This observed blue shift and the increase
in absorbance are a clear indication that TMP incorporate
to SDS micelles. Figure 2(b) shows the relation between the
absorbance of TMP and the various concentrations of SDS.
A decrease in the absorbance observed at the concentrations
below the CMC indicates the molecular complex formationThe Scientiﬁc World Journal 5
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Figure 2: (a) Visible absorption spectra of TMP (4.0 × 10
−5 M) at
various concentrations of SDS at 298K: (1) no SDS, (2) 2mM, (3)
4mM, (4) 8mM, (5) 10mM, (6) 20mM SDS. (b) The absorbance
change of 4.0 × 10
−5 M TMP (below and above the CMC) with the
concentration of SDS.
between cationic drug TMP and anionic SDS molecules due
to the electrostatic interactions. The increase in absorbance
values with increasing surfactant concentrations above the
CMC indicates association of TMP molecules with SDS
micelles. As more drug molecules are incorporated to
micelles, the absorbance values of λmax reaches a limiting
value and becomes almost constant; that is, the amount
of solubilized TMP reaches saturation. The CMC value of
SDS in the presence of TMP was determined spectropho-
tometrically and employed surface tension measurements
as described previously [4, 36]. A good agreement was
found between two methods, and the CMC of SDS was
determined to be 4mM in the presence of 4.0 × 10
−5M
TMP. The absorption spectra of SMX in the presence of
various concentrations of SDS are shown in Figure 3(a).A t
the concentrations below and above the CMC (8.0mM),
no spectral changes were observed, and the absorbance of
SMX remained almost constant in the presence of SDS. As
seen in Figure 3(b) there is a slight increase in absorbance,
that is, only a very weak interaction occurred between SMX
and SDS micelles due to the electrostatic repulsion. Under
working conditions, SMX bears a net negative charge and
SMX anion is dominant form. The spectral behaviour of
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Figure 3: (a) Visible absorption spectra of SMX (4.0 × 10
−5 M) at
various concentrations of SDS at 298K: (1) no SDS, (2) 2mM, (3)
4mM, (4) 8mM, (5) 10mM, (6) 20mM SDS. (b) The absorbance
change of 4.0 × 10
−5 M SMX (below and above the CMC) with the
concentration of SDS.
4.0×10
−5M TMP and SMX in aqueous solutions containing
diﬀerentconcentrationofCDswerestudied.Figures4(a)and
4(b) show the relation between the absorbance of TMP and
SMX with the various concentrations of CDs, respectively.
The increase in absorbance values with increasing CDs
concentrations indicates association of drugs with CDs.
Changes of absorption spectra observed for SMX and TMP
inthepresenceofCDswereanalogical,sointhepresentwork
only the ﬁgures are shown for the most eﬀective CD on the
complexation tendency of SMX and TMP (Figures 5(a) and
5(b)). A similar behavior, that is, a progressive enhancement
in absorbance with the increase of CD concentration, was
observed for all CDs. Figure 5(a) shows UV spectra of
TMP in the presence of various concentrations of γ-CD.
No shift was observed in the λmax of TMP at 274nm when
complexes are formed with α-, β-, and γ-CD. A similar
behavior, that is, a progressive enhancement in absorbance
of SMX, was also observed for SMX in the presence of
various concentrations of β-CD and shown in Figure 5(b).
Fromthespectralmeasurements,thebindingconstantvalues
(Kb) related to the extent of drug-SDS and/or drug-CDs
interactions were calculated using the Benesi-Hildebrand
equation and shown in Table 1. It has been found that6 The Scientiﬁc World Journal
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Figure 4: (a) The absorbance change of 4.0×10
−5 M TMP with the
concentrations of CDs. (b) The absorbance change of 4.0 × 10
−5 M
SMX with the concentrations of CDs.
the interaction between cationic TMP and anionic SDS
micelles is the strongest because of the opposite charge of
the components as expected. The lack of interaction of SMX
withSDSsupportsthisexpectation,andthebindingconstant
of SMX in the case of SDS micelles could not be calculated.
The Kb values of SMX and TMP presented in Table 1 for
the interaction of three types of CDs indicated the diﬀerent
aﬃnities which follow the order as β-CD >γ -CD >α -CD in
the case of SMX and γ-CD >β -CD >α -CD in the case of
TMP. Before discussing on the diﬀerent binding tendency of
drugs to CDs as well as SDS micelles, it is worth mentioning
the data obtained from surface tension measurements. In
order to get a better insight in the mechanism of interaction
ofSMXandTMPwithSDSandCDs,athoroughstudyofthe
surfacetensionchangeofSDSandCDswasperformedinthe
presence of 4.0 × 10
−5 MS M Xa n dT M P .I nt h i ss t u d y ,o n c e
the interfacial behaviours of SDS and CDs were analyzed in
the absence of the drugs. α-, β-, and γ-CD did not show
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Figure 5: (a) Visible absorption spectra of TMP (4.0 × 10
−5 M)
at various concentrations of γ-CD at 298K: (1) no γ-CD, (2)
1mM, (3) 2mM, (4) 4mM, (5) 6mM, (6) 8mM, (7) 10mM γ-
CD.(b) Visibleabsorptionspectra ofSMX (4.0×10
−5 M)at various
concentrations of β-CD at 298K: ↑ (1) no γ-CD, (2) 1mM, (3)
2mM, (4) 3mM, (5) 4mM, (6) 6mM, (7) 8mM, (8) 10mM γ-CD.
any surface property: the measured surface tensions of their
solutions varied in the range of 71.6–72.0mN/mo n l y .A s
already reported in the literature native α-, β-, and γ-CD
were not surface active [19, 43]. Since the same behaviour
was observed for the surface tension measurements at
various concentrations of SDS and CDs in the presence of
4.0 × 10
−5 M SMX and TMP, only the results for TMP are
shown in Figure 6(a) as a representative ﬁgure. As seen in
Figure 6(a), no variation of the surface tension was observed
for the CDs studied even with the increase in concentration
of CD; on the contrary, the acting of SDS is diﬀerent. The
inﬂuences of SMX and TMP on surface properties of SDS
are shown in Figure 6(b) plotted by the surface tension (γ)
versus logarithm of concentration of SDS in the absence
and presence of 4.0 × 10
−5 M TMP and SMX. Using the
concentration dependence of surface tension (Figure 6(b)),
and the Gibbs equation, the quantities of adsorbing SDS
and the apparent area of adsorbed SDS were determined
in the absence and presence of SMX and TMP. The slope
of surface tension (γ) versus ln concentration is propor-
tional to the surface excess (Γmax)a sa p p a r e n tf r o m( 2).The Scientiﬁc World Journal 7
Table 1: K1:1 and KM values for SMX and TMP in the presence of SDS and CDs at 298K. Kb and λmax (nm) values for ﬁxed concentration of
SMX and TMP (4.0 ×10
−5 M )o b t a i n e di nS D Sa n dC D s .
SMX TMP
Kb K1:1 KM λmax/nm Kb K1:1 KM λmax/nm
SDS — — 71.30 260 327.0 — 326.95 271
α-CD 30.15 279.21 — 264 54.09 13.02 — 273
β-CD 240.10 489.26 — 270 110.0 36.85 — 274
γ-CD 95.44 317.53 — 263 226.40 79.50 — 274
Table 2: Estimated surface excess (Γmax) and molecular occupied area (Amin) for SDS and TX100 in the absence and presence of 4.0×10
−5 M
SMX and TMP at 298K.
SMX TMP
Γmax (mmol/m2)A min× 10−2(˚ A2) Γmax (mmol/m2)A min× 10−2 (˚ A2)
SDS 5.23 3.17 2.99 5.55
TX100 2.55 6.51 3.02 5.50
No drugs
Γmax (mmol/m2)A min× 10−2(˚ A2)
SDS 3.66 4.54
TX100 2.47 6.70
Table 2 summaries the corresponding Γmax and Amin values.
As seen in Figure 6(b) the surface tension values of SDS in
the presence of TMP are lower than those in the absence
of TMP. On the contrary, the surface tension values of SDS
in the presence of SMX is little higher than those in the
absence of SMX. The data in Table 2 show that Γmax value
of SDS increased and Amin decreased in the presence of SMX
while Γmax value of SDS decreased and Amin increased in the
presence of TMP. These ﬁndings support that electrostatic
forces play an important role on the interaction between the
drugs and SDS. The presence of TMP decreasesthe repulsion
among head groups of SDS, and more TMP molecules can
be adsorbed at the interface which is also conﬁrmed by the
higher value of Amin; that is, TMP increased the adsorption
of SDS at the interface. The higher the Γmax value and the
lower the Amin value for SDS in the presence of SMX also
explains that the electrostatic repulsion forces take place in
the interaction of anionic SMX and anionic SDS molecules
compared to a pure SDS solutions. In order to gain better
insight into the phenomena taking place at the interface,
the surface tension measurements were also performed for
nonionic surfactant Tritonx-100 (TX-100) in the presence of
SMX and TMP at 298K. The variation of surface tension
as a function of TX-100 concentration in the absence and
presence of 4.0 × 10
−5 M SMX and TMP is also illustrated
in Figure 6(c), and the data obtained from surface tension
measurements presented in Table 2 in order to compare
with the behaviour of SMX and TMP in the presence of
ionic and nonionic micellar environments. It is also clearly
seen that the surface tension values of TX-100 did not
vary signiﬁcantly as in the case of SDS with the addition
of SMX and TMP; that is, the smaller increase of surface
tension values of TX-100 was observed. Γmax value of TX-100
increased,andAmin decreasedinthepresenceofTMPasseen
in Table 2.H o w e v e r ,b o t hΓmax and Amin values of TX-100
remained almost the same as in the presence of SMX. It can
be said that electrostatic forces take place in binding of SMX
and TMP onto anionic SDS micelles, whereas hydrophobic
interaction plays the main role in binding of SMX and
TMP to nonionic TX-100 micelles. There is a reasonable
agreement with the value obtained from spectrophotometric
measurements due to the lack of interaction between SDS
and SMX; that is, electrostatic repulsion forces overcome
hydrophobic interaction.
3.2.MicellarSolubilizationofSMXandTMPbySDSandCDs.
Figure 7(a) shows the solubility change of poorly soluble
model drugs SMX and TMP as a function of SDS concen-
tration. As seen in Figure 7(a), the plots of drug solubility
against surfactant concentrations can be divided into two
straight lines; one for below the CMC (8mM) and the
other above it. Above the CMC solubility of drugs increased
with the increase in SDS concentration and good linearity
was observed between the surfactant concentration and the
solubility. The solubilization capacity KM was determined to
be 71.30 and 326.95M−1 for SMX and TMP, respectively.
These results obtained from (4)a n dg i v e ni nT a b l e1 are
compatible with the results of interaction studies discussed
in the previous section. The solubility of SMX and TMP in
the aqueous SDS solutions increased linearly with increase
of the SDS concentration. Solubilization eﬀect of SDS on
TMP is stronger than that of SMX. This behaviour is a
consequence of the electrostatic interactions between the
negatively charged surfactant SDS and cationic drug TMP.
As indicated in the interaction studies, the addition of TMP
caused a decrease in the repulsive forces between the head8 The Scientiﬁc World Journal
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Figure 6: (a) Surface tension results for SDS and CDs in the
presenceof4.0×10
−5 MTMPat298K.(b)Surfacetensionversusln
(concentration) plots for SDS in the absence ()a n dp r e s e n c eo f
4.0 × 10
−5 MS M X( ) and TMP(+) at 298K. (c) Surface tension
versus ln (concentration) plots for TX100 in the absence ()a n d
presence of 4.0 ×10
−5 MS M X( ) and TMP(+) at 298K.
0
2
4
6
8
10
01 0 2 0 3 0 4 0 5 0 60
SDS (mM)
D
r
u
g
 
s
o
l
u
b
i
l
i
t
y
 
(
m
M
)
TMP
SMX
CMC
(a)
0
2
4
6
8
02468 1 0
CD (mM)
S
M
X
 
(
m
M
)
α-CD
β-CD
γ-CD
(b)
1
1.4
1.8
2.2
02468 1 0
CD (mM)
T
M
P
 
(
m
M
)
α-CD
β-CD
γ-CD
(c)
Figure 7: (a) Solubility curves of SMX and TMP as a function of
SDS concentration at 298K. (b) Phase solubility diagrams of SMX-
CD systems at 298K. (c) Phase solubility diagrams of TMP-CD
systems at 298K.
groups of SDS molecules, contributing to the micellization
process, and thus the CMC value of SDS decreased from
8mM to 4mM. This is also supported by the inﬂuence of
SMX and TMP on the surface properties of SDS based on
surface tension measurements.The Scientiﬁc World Journal 9
3.3. Complexation of SMX and TMP by CDs. Figures 7(b)
and 7(c) show the solubilization data of two model drugs
SMX and TMP as a function of the CD concentrations,
respectively. The solubility proﬁle showed an increase in
their solubility when the concentrations of CDs increase.
The 1:1 drug/CD complexes are typical of association where
a single drug molecule is in the cavity of a CD, with a
stability constant (K1:1) for the equilibrium between the
free and associated species. As seen in Figures 7(b) and
7(c), the solubility of SMX and TMP increased linearly
as a function of CD concentration, and phase solubility
studies revealed increase in solubility of the drug upon
cyclodextrin addition, showing AL type of graph with slope
less than one indicating formation of 1:1 stochiometry
inclusion complex. The corresponding stability (or complex
formation) constants are listed in Table 1. The apparent
solubilities (S0) of SMX (2.1 × 10
−3 M) and TMP (1.4 ×
10
−3 M) in water obtained from phase solubility diagrams
are close enough to the value of 2.40 × 10
−3Mf o rS M X
and 1.38 × 10
−3 M for TMP as reported previously [42]. It
is clearly seen that the stability of the inclusion complexes
is in the diﬀerent order for SMX and TMP. The stability
constant K1:1 values for the TMP/CD system followed the
order γ-CD >β -CD >α -CD. However, the diﬀerent trend
was observed in the case of SMX/CD system and followed
the order β-CD >γ -CD >α -CD. Host complexation is
primarily determined by the tightness of the ﬁt, that is, by
the size and shape matching between the guest and the CD
cavity. CDs are designated α, β,o rγ corresponding to 6,
7, or 8 glucopyranose units, with cavity diameters of 4.7–
5.3, 6.0–6.5, and 7.5–8.3 ˚ A, respectively [44]. Based on these
dimensions α-CD can typically complex low-molecular-
weight molecules or compounds with aliphatic side chains,
β-CD will complex aromatics and heterocycles and γ-CD
can accommodate larger molecules such as macrocycles and
steroids. If the guest is the imperfect size, it will not ﬁt
properly into the cyclodextrins cavity and leads to a decrease
in the host-guest interactions as well as the association
constants [45]. The diﬀerent ability of CDs to associate with
TMP seems to be related with the ﬁtting of the substrate into
the CD cavity. The TMP molecule is approximately 7.39 ˚ Ai n
widthand11.972 ˚ Ainlength[46].Consequently,theinternal
diameters of the α-CD and β-CD cavities are too small
for inclusion of the TMP molecules. The internal diameter
of γ-CD cavity is suitable for accommodation of the TMP
molecule. The relatively high K1:1 value for complexation of
TMP with γ-CD indicates the existence of a better geometric
ﬁt than that with the α-o rβ-CD cavities. However, the
diﬀerent trend was observed in the case of SMX for the
inclusion complex formation based on the dimensions of
CDs. As data in Table 1 show, α-CD behaves similarly to γ-
CD, but its ability to associate with SMX is relatively smaller.
One of the most interesting results of the present study is
the lack of complexation of SMX with γ-CD. However, the
capability of β-CD to form complexes with SMX seems to be
stronger than the inclusion complex formation tendency of
SMX with α-a n dγ-CD. The reported molecular dimension
o ft h eS M Xm o l e c u l ei sa p p r o x i m a t e l y5 . 6 ˚ A in width
and 12.9 ˚ A in length according to Comerton et al. [47].
The weak inclusion complex formation of SMX with α-CD
can be explained with the smaller internal diameter cavity
of α-CD. Thus, SMX molecule should be tightly packed into
the γ-CD cavity. Although prediction of compound solubi-
lization by CDs continues to be highly empirical, various
historical observations permit several general statements.
The formation of an inclusion complex with cyclodextrins
is also classically caused by interactions such as hydrogen
bonding with the OH groups at the periphery of the cavity,
van der Waals interactions, and hydrophobic eﬀects [48].
Hydrophobic interactions should play an important role for
thestrongerinclusioncomplexformationofSMXwithβ-CD
ascomparedwiththatofα-andγ-CD.Whenwecomparethe
aqueous solubility of α- (14.5%, w/v), β- (1.85%, w/v), and
γ-CD (23.2%, w/v) in water [20], it can be resulted that γ-
CD is the most soluble whereas β-CD is the least soluble in
water; that is, β-CD is more hydrophobic than γ-CD. The
interaction studies performed for the ﬁxed concentration
of SMX supports the behaviour of SMX in the presence of
β-CD. The maximum absorption spectra of SMX shifted
from 265nm to 270nm in the presence of β-CD while
the maximum absorption spectra of SMX did not change
signiﬁcantly in the presence of α-a n dγ-CD.
3.4. Probable Location of TMP and SMX: Eﬀect of Medium
Polarity. As mentioned above the characteristics of the
absorptionspectraofSMXandTMPshoweddiﬀerenttrends
in the presence of SDS, α-, β-, and γ-CD. These observations
are indicative of change in the microenvironmental polarity
of the drugs due to interactions with SDS and CDs. To gain
insight into the localization of SMX and TMP in SDS and
CDs, we have studied the spectrophotometric behavior of
SMX and TMP in the presence of various organic solvents
with diﬀerent polarity such as ethanol (EOH), propylene
glycol (PG), ethylene glycol (EG), and glycerin (Gly). Figures
8(a) and 8(b) present the absorption spectra of 4.0 ×10
−5 M
TMP and SMX, respectively, in the presence of various
organic solvents for the sake of comparison also in water.
Comparison of diﬀerent shifts in the presence of these
organic solvents indicates the order of the polarity of the
media follow the trend; water > Gly > PG > EG > EOH.
This follows the same increasing order of λmax of TMP. The
λmax of TMP at 274nm in water shifted to 273, 281, 289,
and 290nm in the presence of Gly, PG, EG, and EOH,
respectively. Our data showed that, upon going from the
more hydrophilic to the more hydrophobic environment,
TMP underwent a red shift in the absorption maximum
(Figure 8(a)). The red shift is also a clear indication
of the tendency of TMP to less polar environment. The
λmax values given in Table 1 support these ﬁndings in
the presence of SDS and CDs. The parallelism between
polarity of the medium and higher micellar binding constant
demonstrates signiﬁcantly that hydrophobic interactions
play an important role in solubilization of TMP by SDS
micelles beside electrostatic interactions. The small blue
shift in the presence of Gly also supports the behaviour
of TMP in the presence of SDS; that is, Gly is more
hydrophilic than the other solvents studied. It can be said10 The Scientiﬁc World Journal
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Figure 8: (a) Variation of visible absorption spectra of SMX (4.0 ×
10
−5 M) in the absence and presence of various solvents at 298K:
(1) in water, (2) Gly, (3) PG, (4) EOH, (5) EG. (b) Variation of
visible absorption spectra of TMP (4.0 × 10
−5 M) in the absence
and presence of various solvents at 298K: (1) in water, (2) Gly, (3)
PG, (4) EOH, (5) EG.
that TMP is located in the interfacial region of SDS micelles
while in the case of CDs TMP prefers to locate in the
hydrophobic region depending on the cavity size. As seen
in Table 1, in contrast with TMP, the absorption maxima
of SMX is red shifted by 5nm in β-CD, whereas blue
shifted 1–3nm in α-a n dγ-CD compared with those in
aqueous medium. These observed shifts show that SMX
is transferred from a highly polar phase (H2O) to a less
polar phase. This is supported with the red shift (from 265
to 272nm) obtained when Gly, PG, EG, and EOH were
used as solvent instead of water. As seen in Figure 8(b) no
signiﬁcant shifts of the λmax of SMX were observed with
the change of medium polarity. The higher binding constant
of SMX determined in the presence of β-CD conﬁrms the
more binding tendency of SMX due to more hydrophobic
character of β-CD.TheinclusioncomplexformationofSMX
with β-CD might be explained with only a part of the SMX
molecule accommodated in the β-CD cavity and leaving
the rest of the molecule protruding into water taking into
consideration molecular geometry. The spectral behaviour
of SMX in the presence of organic solvents indicates that
SMX is willing to transfer more hydrophobic region. This
is conﬁrmed that the electrostatic repulsion forces are
dominant on the interaction between SMX and SDS in
aqueous media; that is, no signiﬁcant shift was observed
in the spectrum of SMX in the presence of SDS. The
surface excess and molecular occupied area obtained from
surface tension measurements also conﬁrm these results (see
S1 and S2 in Supplementary Material available online at
doi:10.1100/2012/718791).
4. Conclusions
In this work the solubilizing ability of three diﬀerent CDs
(α-, β-, and γ-CD) and SDS were compared for two
poorly soluble drugs, that is, SMX and TMP based on
spectrophotometric and surface tension measurements. An
extensive study on the solubilization characteristics of SMX
and TMP in diﬀerent environmental conditions has been
presented at 298K. To obtain more information about the
nature and properties of the solubilization of the drugs by
diﬀerent structures for the ﬁxed concentration of the drugs,
as a model system for biomembranes, interactions of SMX
and TMP with SDS and CDs were studied separately. The
aqueous solubility of poorly soluble drugs can considerably
be improved by micellar solubilization. The increases of the
aqueous solubility of SMX and TMP in the presence of α-,
β-, and γ-CD indicate that they are able to form inclusion
complexes with diﬀerent manner. Stability or equilibrium
constants of the drug-CD complexes are important since this
is an index of changes in physicochemical properties of a
compound upon inclusion. Solubility of drugs in various
media and the binding constants of drugs into CDs and SDS
m i c e l l e sw e r ef o u n dt od e p e n do nd r u gc h a r a c t e r i s t i c sa s
well. The solubilization of TMP with diﬀerent CDs revealed
thatcomplexstabilityisaﬀectedbythegeometricﬁtwithCD.
However,thehighertendencyofSMXtocomplexwithβ-CD
in aqueous solution is governed by the hydrophobic eﬀect.
Changes in surface properties of surfactants determined by
surface tension measurements in the presence of drugs are
in good agreement with the binding constants determined
spectrophotometrically. Therefore, it is important to study
the change in surface properties to understand the action
mechanism of the drug especially in the case of surfactants.
Another interesting point is that the diﬀerent tendency was
observed in the absorption maxima of SMX and TMP in
the presence of various organic solvents. The λmax values
of SMX and TMP in the presence of CDs or SDS and
organic solvents are in conformity with the localization of
SMX and TMP for complexation and solubilization manner.
As a conclusion, the presented results should be of special
interest in the pharmaceutical researches in drug delivery
systems.
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